Mp01-15 Germ Cell Tumors in the Us Military: A Critical Analysis of Presentation and Treatment

You have accessJournal of UrologyPenile & Testicular Cancer I (MP01)1 May 2024MP01-15 GERM CELL TUMORS IN THE US MILITARY: A CRITICAL ANALYSIS OF PRESENTATION AND TREATMENT Tarah Woodle, Eric Umbreit, Evan Crockett, and Leah Williams Tarah WoodleTarah Woodle , Eric UmbreitEric Umbreit , Evan CrockettEvan Crockett , and Leah WilliamsLeah Williams View All Author Informationhttps://doi.org/10.1097/01.JU.0001008660.87408.90.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Germ cell tumors (GCT) present a significant risk to young men in the United States military, with an incidence of nearly ten times higher than that of the general population. Moreover, military aviators face an even higher incidence of testicular cancer compared to other military personnel. The military healthcare system (MHS) offers a distinctive setting where beneficiaries have access to both military and out of network providers, eliminating the barrier of limited access to care. Leveraging this unique equitable healthcare platform, our study aims to conduct an assessment of the diagnosis and treatment of testicular GCT within the United States military. METHODS: We performed a retrospective review of patients diagnosed with testicular cancer within the MHS from 2000 to 2020. Specifically epidemiologic data, clinical practice patterns, and clinical outcomes were collected. Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. RESULTS: 401 patients had confirmed GCT on pathologic evaluation, with NSGCT and seminoma accounting for 43% and 52% of patients, respectively. In total, 83% of patients were active duty and 30% of patients with known job descriptions were military aviators. NSGCT patients presented with stage 1, 2 and 3 disease in 55%, 25% and 18%, respectively. Stage 1A disease was managed with active surveillance in only 64% pts. For stage 1B disease, active surveillance was utilized in 25% of eligible patients. Among patients with seminoma, 74%, 19% and 6% were stage 1, 2 and 3, respectively. Stage 1 seminoma patients underwent active surveillance as primary treatment in 67% of patients. Only 1 cancer related death was reported in the entire cohort. CONCLUSIONS: Despite access to care and the higher incidence of testicular germ cell tumor within the US military, active surveillance protocols were consistently underutilized. In cases of low-risk disease, we observed a substantial utilization of adjuvant therapy for both NSGCT (48%) and seminoma (38%), indicating aggressive practice patterns in light of current NCCN guidelines. Furthermore, our study validates the increased incidence of testicular cancer in military aviators. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e8 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Tarah Woodle More articles by this author Eric Umbreit More articles by this author Evan Crockett More articles by this author Leah Williams More articles by this author Expand All Advertisement PDF downloadLoading ...